Idera Pharmaceuticals Provides Update On IMO-2055 Clinical Development Program
7/08/2011

Idera Pharmaceuticals (NASDAQ: IDRA) today provides an update on the clinical development of IMO-2055 (EMD 1201081), a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera...

Synta Announces Presentation Of Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results At IASLC 14th World Conference On Lung Cancer
7/08/2011

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today presented results at the International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease...

Researchers Examine How Genes And Proteins Affect Therapeutic Treatments For Lung Cancer
7/08/2011

The Translational Genomics Research Institute (TGen) presented two key studies at the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam. One study involved a gene called GLI1, which may limit the effectiveness of the most common combination chemotherapy given to patients with small cell lung cancer (SCLC)...

Mediator MED26 Shifts An Idling Polymerase Into High Gear In The Control Of Gene Expression
7/08/2011

Look up "transcription" - the copying of a gene's DNA into RNA intermediaries - in any old molecular biology text book, and it all seems very simple: RNA polymerase II, the enzyme that catalyzes the reaction, assembles at the start site and starts motoring down the strand, cranking out the RNA ribbon used to construct proteins...

Identification Of Cellular Origin Of Deadly Brain Cancer
7/08/2011

Using a mouse genetic system co-developed by researchers at the University of Oregon and Stanford University, a research team led by UO biologist Hui Zong has isolated the cellular origin for malignant glioma, a deadly human brain cancer...

Amrubicin Improved Response Rate And Progression-Free Survival Vs. Topotecan For Lung Cancer Patients In Phase III Trial
7/08/2011

Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC)...

In Non-Small Cell Lung Cancer Patients, TEMLA Shows Higher Diagnostic Yield Than EBUS Or EUS In Largest Reported Series To Date
7/08/2011

In the largest reported series yet to compare transcervical extended mediastinal lymphadenectomy (TEMLA) with endoscopic and surgical primary staging and restaging of non-small cell lung cancer (NSCLC), TEMLA showed a significantly higher diagnostic yield, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Assoc...

For Lung Cancer Patients Endosonography Followed By Surgical Staging Improves Quality Of Life, According To ASTER Study
7/08/2011

Patients who underwent endoscopic testing prior to surgery for lung cancer had significantly better quality of life at the end of the staging process, with no significant difference in costs between the two strategies, according to data presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC)...

Man Receives New Windpipe Made From His Own Stem Cells And Artificial Material
7/08/2011

Last month in Sweden, a man suffering from late-stage tracheal cancer received a new windpipe made in the lab from a synthetic scaffold with flesh grown from his own stem cells. This is the first successful transplant in the world of a tissue-engineered trachea that does not use a scaffold made from a donor organ...

Canary Foundation Researchers Receive Department Of Defense Grants For Over $2 Million To Fund Prostate Cancer Research
7/08/2011

Canary Foundation's Canary Prostate Team has been awarded two Department of Defense (DOD) grants issued by the United States Army Medical Research Acquisition Activity (USAMRAA). Totaling $2.25 million, these grants will help fund prostate cancer research led by Peter Carroll, MD, Ziding Feng, PhD, and James Brooks, MD. Dr...